10:15 AM - 11:30 AM
on Monday, Apr 22, 2013
Description:
Rising regulatory and reimbursement hurdles are putting pressure on biopharma’s commercial engines, and redefining the term "blockbuster." Part of the industry’s response has been to embrace more niche indications, where lower...